Jagsonpal Pharmaceuticals Revenue vs. Current Valuation

JAGSNPHARM   636.65  9.80  1.52%   
Based on Jagsonpal Pharmaceuticals' profitability indicators, Jagsonpal Pharmaceuticals Limited may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Jagsonpal Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2011-09-30
Previous Quarter
614.4 M
Current Value
746.9 M
Quarterly Volatility
108.9 M
 
Yuan Drop
 
Covid
For Jagsonpal Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Jagsonpal Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Jagsonpal Pharmaceuticals Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Jagsonpal Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Jagsonpal Pharmaceuticals Limited over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
Please note, there is a significant difference between Jagsonpal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jagsonpal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jagsonpal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Jagsonpal Pharmaceuticals Current Valuation vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Jagsonpal Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Jagsonpal Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Jagsonpal Pharmaceuticals Limited is considered the number one company in revenue category among its peers. It also is considered the number one company in current valuation category among its peers reporting about  7.80  of Current Valuation per Revenue. As of now, Jagsonpal Pharmaceuticals' Total Revenue is increasing as compared to previous years. Comparative valuation analysis is a catch-all model that can be used if you cannot value Jagsonpal Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Jagsonpal Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Jagsonpal Revenue vs. Competition

Jagsonpal Pharmaceuticals Limited is considered the number one company in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 15.21 Trillion. Jagsonpal Pharmaceuticals adds roughly 2.09 Billion in revenue claiming only tiny portion of equities under Health Care industry.

Jagsonpal Current Valuation vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Jagsonpal Pharmaceuticals

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
2.09 B
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Jagsonpal Pharmaceuticals

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
16.28 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Jagsonpal Current Valuation vs Competition

Jagsonpal Pharmaceuticals Limited is considered the number one company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 61.47 Trillion. Jagsonpal Pharmaceuticals adds roughly 16.28 Billion in current valuation claiming only tiny portion of equities under Health Care industry.

Jagsonpal Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Jagsonpal Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Jagsonpal Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Jagsonpal Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Jagsonpal Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income588.7 M618.2 M
Operating Income214 M111.4 M
Income Before Tax298.7 M313.6 M
Total Other Income Expense Net84.7 M88.9 M
Net Income224.6 M116.5 M
Income Tax Expense74.1 M77.8 M
Net Income From Continuing Ops224.6 M235.9 M
Net Income Applicable To Common Shares307.3 M322.7 M
Interest Income3.7 M3.5 M
Net Interest Income-8.1 M-7.7 M
Change To Netincome102.2 M107.3 M

Jagsonpal Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Jagsonpal Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Jagsonpal Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Jagsonpal Pharmaceuticals' important profitability drivers and their relationship over time.

Use Jagsonpal Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jagsonpal Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jagsonpal Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Jagsonpal Pharmaceuticals Pair Trading

Jagsonpal Pharmaceuticals Limited Pair Trading Analysis

The ability to find closely correlated positions to Jagsonpal Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jagsonpal Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jagsonpal Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jagsonpal Pharmaceuticals Limited to buy it.
The correlation of Jagsonpal Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jagsonpal Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jagsonpal Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jagsonpal Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Jagsonpal Pharmaceuticals position

In addition to having Jagsonpal Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Long Short Funds Thematic Idea Now

Long Short Funds
Long Short Funds Theme
Funds or Etfs that are designed to hedge away market risk by investing in combination of bonds, stocks, derivative instruments as well as short positions to maximize returns irrespective of market conditions. The Long Short Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long Short Funds Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Jagsonpal Stock

To fully project Jagsonpal Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Jagsonpal Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Jagsonpal Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Jagsonpal Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Jagsonpal Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Jagsonpal Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Jagsonpal Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.